Axsome Net Income Applicable To Common Shares from 2010 to 2026

AXSM Stock  USD 185.27  0.10  0.05%   
Axsome Therapeutics Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to grow to about -160 M this year. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2013-12-31
Previous Quarter
-67.2 M
Current Value
-62.2 M
Quarterly Volatility
18.1 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Axsome Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Axsome Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.6 M, Interest Expense of 7.9 M or Selling General Administrative of 374.5 M, as well as many indicators such as Price To Sales Ratio of 11.48, Dividend Yield of 0.0 or PTB Ratio of 67.19. Axsome financial statements analysis is a perfect complement when working with Axsome Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Axsome Stock
Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Latest Axsome Therapeutics' Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Axsome Therapeutics over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Axsome Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Axsome Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Axsome Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(77,693,717)
Coefficient Of Variation(97.35)
Mean Deviation68,149,186
Median(30,965,464)
Standard Deviation75,636,887
Sample Variance5720.9T
Range181.1M
R-Value(0.92)
Mean Square Error920.7T
R-Squared0.85
Slope(13,802,208)
Total Sum of Squares91535T

Axsome Net Income Applicable To Common Shares History

2026-160 M
2025-168.4 M
2022-187.1 M
2021-130.4 M
2020-102.9 M
2019-68.3 M
2018-31 M

About Axsome Therapeutics Financial Statements

Axsome Therapeutics investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how Axsome Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-168.4 M-160 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(4.66)
Revenue Per Share
11.402
Quarterly Revenue Growth
0.632
Return On Assets
(0.20)
Return On Equity
(2.75)
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.